COL-3 may stop the growth of cancer by stopping blood flow to the tumor. Randomized phase II trial to compare the effectiveness of two different regimens of COL-3 in treating patients who have HIV-related Kaposi's sarcoma.

Start Date01 Mar 2003

Sponsor / Collaborator

National Cancer Institute

NCT00004147 / CompletedPhase 1/2IIT

A Phase I/II Study of Col-3 Administered on a Continuous Daily Oral Schedule in Patients With Recurrent High-Grade Astrocytoma

RATIONALE: COL-3 may stop the growth of brain tumors by stopping blood flow to the tumor.
PURPOSE: Phase I/II trial to study the effectiveness of COL-3 in treating patients who have progressive or recurrent brain tumors following radiation therapy or chemotherapy.

Start Date01 Jul 2000

Sponsor / Collaborator

National Cancer Institute

NCT00003721 / CompletedPhase 1IIT

A Phase I, Pharmacologic and Biologic Study of Col-3 (NSC683551) Administered on a 28-Day Oral Dosing Schedule in Patients With Advanced Solid Tumors

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase I trial to study the effectiveness of COL-3 in treating patients who have advanced solid tumors.

Start Date01 Nov 1998

Sponsor / Collaborator

University of Texas Health Science Center At San Antonio

[+1]

100 Clinical Results associated with Incyclinide

100 Translational Medicine associated with Incyclinide

100 Patents (Medical) associated with Incyclinide

107

Literatures (Medical) associated with Incyclinide

01 May 2023·Computers in Biology and Medicine

Identification of key genes in colorectal cancer diagnosis by weighted gene co-expression network analysis

Article

Author: Afshar, Saeid ; Mortezapour, Mahdie ; Bahreini, Fatemeh ; Najafi, Rezvan ; Tapak, Leili

BACKGROUNDThe purpose of this study was using bioinformatics tools to identify biomarkers and molecular factors involved in the diagnosis of colorectal cancer, which are effective for the diagnosis and treatment of the disease.METHODSWe determined differentially expressed genes (DEGs) related to colorectal cancer (CRC) using the data series retrieved from GEO database. Then the weighted gene co-expression network analysis (WGCNA) was conducted to explore co-expression modules related to CRC diagnosis. Next, the relationship between the integrated modules with clinical features such as the stage of CRC was evaluated. Other downstream analyses were performed on selected module genes.RESULTSIn this study, after performing the WGCNA method, a module named blue module which was more significantly associated with the CRC stage was selected for further evaluation. Afterward, the Protein-protein interaction network through sting software for 154 genes of the blue module was constructed and eight hub genes were identified through the evaluation of constructed network with Cytoscape. Among these eight hub genes, upregulation of MMP9, SERPINH1, COL1A2, COL5A2, COL1A1, SPARC, and COL5A1 in CRC was validated in other microarray and TCGA data. Based on the results of the mRNA-miRNA interaction network, SERPINH1 was found as a target gene of miR-940. Finally, results of the DGIDB database indicated that Andecaliximab, Carboxylated glucosamine, Marimastat, Tozuleristide, S-3304, Incyclinide, Curcumin, Prinomastat, Demethylwedelolactone, and Bevacizumab, could be used as a therapeutic agent for targeting the MMP9. Furthermore, Ocriplasmin and Collagenase clostridium histolyticum could target COL1A1, COL1A2, COL5A1, and COL5A2.CONCLUSIONTaken together, the results of the current study indicated that seven hub genes including COL1A2, COL5A1, COL5A2, SERPINH1, MMP9, SPARC, and COL1A1 which were upregulated in CRC could be used as a diagnostic and progression biomarker of CRC. On the other hand, miR-940 which targets SERPINH1 could be used as a potential biomarker of CRC. More ever, Andecaliximab, Carboxylated glucosamine, Marimastat, Tozuleristide, S-3304, Incyclinide, Curcumin, Prinomastat, Demethylwedelolactone, Bevacizumab, Ocriplasmin , and Collagenase clostridium histolyticum were introduced as therapeutic agents for CRC which their therapeutic potential should be evaluated experimentally.

25 Apr 2023·Proceedings of the National Academy of Sciences of the United States of AmericaQ1 · CROSS-FIELD

Computational drug discovery for castration-resistant prostate cancers through in vitro drug response modeling.

Q1 · CROSS-FIELD

Article

Author: Ho, Yeung ; Su, Mei-Chi ; Huang, R Stephanie ; Jena, Sampreeti ; Lee, Adam M ; Dehm, Scott M ; Miller, Conor R ; Huang, Yingbo ; Mentzer, Joshua ; Li, Yingming ; Zhang, Weijie ; Ling, Alexander L ; Tietz, Kiel T

Prostate cancer (PC) is the most frequently diagnosed malignancy and a leading cause of cancer deaths in US men. Many PC cases metastasize and develop resistance to systemic hormonal therapy, a stage known as castration-resistant prostate cancer (CRPC). Therefore, there is an urgent need to develop effective therapeutic strategies for CRPC. Traditional drug discovery pipelines require significant time and capital input, which highlights a need for novel methods to evaluate the repositioning potential of existing drugs. Here, we present a computational framework to predict drug sensitivities of clinical CRPC tumors to various existing compounds and identify treatment options with high potential for clinical impact. We applied this method to a CRPC patient cohort and nominated drugs to combat resistance to hormonal therapies including abiraterone and enzalutamide. The utility of this method was demonstrated by nomination of multiple drugs that are currently undergoing clinical trials for CRPC. Additionally, this method identified the tetracycline derivative COL-3, for which we validated higher efficacy in an isogenic cell line model of enzalutamide-resistant vs. enzalutamide-sensitive CRPC. In enzalutamide-resistant CRPC cells, COL-3 displayed higher activity for inhibiting cell growth and migration, and for inducing G1-phase cell cycle arrest and apoptosis. Collectively, these findings demonstrate the utility of a computational framework for independent validation of drugs being tested in CRPC clinical trials, and for nominating drugs with enhanced biological activity in models of enzalutamide-resistant CRPC. The efficiency of this method relative to traditional drug development approaches indicates a high potential for accelerating drug development for CRPC.

01 Feb 2023·Biomechanics and Modeling in Mechanobiology

Surrogate modeling of articular cartilage degradation to understand the synergistic role of MMP-1 and MMP-9: a case study

Article

Author: Dhaher, Yasin Y ; Adouni, Malek ; Faisal, Tanvir R

A characteristic feature of arthritic diseases is cartilage extracellular matrix (ECM) degradation, often orchestrated by the overexpression of matrix metalloproteinases (MMPs) and other proteases. The interplay between fibril level degradation and the tissue-level aggregate response to biomechanical loading was explored in this work by a computational multiscale cartilaginous model. We considered the relative abundance of collagenases (MMP-1) and gelatinases (MMP-9) in surrogate models, where the diffusion (spatial distribution) of these enzymes and the subsequent, co-localized fibrillar damage were spatially randomized with Latin Hypercube Sampling. The computational model was constructed by incorporating the results from prior molecular dynamics simulations (tensile test) of microfibril degradation into a hyper-elastoplastic fibril-reinforced cartilage model. Including MMPs-mediated collagen fibril-level degradation in computational models may help understand the ECM pathomechanics at the tissue level. The mechanics of cartilage tissue and fibril show variations in mechanical integrity depending on the different combinations of MMPs-1 and 9 with a concentration ratio of 1:1, 3:1, and 1:3 in simulated indentation tests. The fibril yield (local failure) was initiated at 20.2 ± 3.0 (%) and at 23.0 ± 2.8 (%) of bulk strain for col 1:gel 3 and col 3: gel 1, respectively. The reduction in failure stress (global response) was 39.8% for col 1:gel 3, 37.5% for col 1:gel 1, and 36.7% for col 3:gel 1 compared with the failure stress of the degradation free tissue. These findings indicate that cartilage's global and local mechanisms of failure largely depend on the relative abundance of the two key enzymes-collagenase (MMP-1) and gelatinase (MMP-9) and the spatial characteristics of diffusion across the layers of the cartilage ECM.

News (Medical) associated with Incyclinide

22 Feb 2021

·www.biospace.com

Clinical Catch-Up: February 15-19

It was a busy week for clinical trial announcements. Here’s a look. COVID-19-Related All India Institute of Medical Sciences (AIIMS) indicated that Bharat Biotech’s COVID-19 vaccine, Covaxin, may offer immunity for nine to 12 months, based on mathematical models. The vaccine was already approved before the release of Phase III data and was used to inoculate healthcare workers during the Phase I trial. Clene Nanomedicine initiated a Phase II trial of CNM-ZnAg liquid solution in acutely symptomatic, non-hospitalized COVID-19 patients. The primary endpoint will evaluate the rate of decreased hospitalizations at day 28. CNM-ZnAg is a proprietary zinc-silver ionic solution that has both antiviral and antibacterial properties as well as immune-boosting properties. Oxford University announced it began testing its COVID-19 vaccine in children as young as six years of age. The study will include 300 children ages 6 to 17, with 240 receiving the vaccine co-developed with AstraZeneca. The remaining volunteers will receive a control meningitis vaccine that has been proven safe in children but is believed to mimic side effects of the COVID-19 vaccine. Mesoblast Limited published results on the first two children treated with its mesenchymal stromal cell (MSC) product candidate, remestemcel-L for multisystem inflammatory syndrome (MIS-C) associated with COVID-19. MIS-C is a potentially life-threatening inflammatory conditions involving multiple critical organs and their vasculature. It is linked to previous, instead of active COVID-19 infection. PTC Therapeutics initiated the second stage of the Phase II/III FITE19 clinical trial of PTC299 in COVID-19 patients. PTC299 is an oral drug with dual mechanisms of action that potentially inhibits viral replication and attenuates the uncontrolled inflammatory response post-infection. The drug targets dihydroorotate dehydrogenase (DHODH). Altimmune received the go-ahead from the FDA for its Phase I trial of AdCOVID, its single-dose, intranasal COVID-19 vaccine. It will test the safety and immunogenicity of the vaccine in up to 180 healthy adult volunteers ages 18 to 55. Pharma Mar SA received approval in the UK to initiate its Phase III NEPTUNO trial of Aplidin (plitidepsin) for hospitalized patients with moderate COVID-19. The trial is expected to run in 12 countries but was first authorized in the UK. It hopes to enroll more than 600 patients. Aplidin blocks the eEF1A protein, which SARS-CoV-2 uses to replicate and infect other cells. Biophytis SA began patient recruitment in France and Belgium for Part 2 of its COVA Study assessing Sarconeos for acute respiratory failure associated with COVID-19. Sarconeos is an oral, small molecule being developed for sarcopenia and severe respiratory aspects of COVID-19, as well as in a pediatric formulation for Duchenne muscular dystrophy (DMD). EmitBio announced statistically significant efficacy results from its Phase I/II trial of its medical device that directs precise wavelengths of safe, visible light targeted to the back of the throat and surrounding tissues. The device was designed for self-treatment of COVID-19 in an at-home setting. Diffusion Pharmaceuticals completed and announced topline data from its Phase Ib trial of its diffusion-enhancing therapeutic, trans sodium crocetinate, in hospitalized COVID-19 patients with confirmed hypoxemia. The primary endpoint was safety and tolerability, with secondary endpoints being pharmacokinetic measurement of trans sodium crocetinate levels after dosing, relative improvements in blood oxygen levels, and other clinical measures associated with COVID-19. Pfizer and BioNTech dosed the first patients in a clinical trial of 4,000 women in the late stages of pregnancy yesterday. The two companies will run the Phase II trial for 350 volunteers between 27 and 34 weeks’ gestation to confirm safety before moving into the Phase III portion for women between 24 and 34 weeks of pregnancy. AstraZeneca and Johnson & Johnson also plan to run trials in the coming months on pregnant women. CMTx Biotech received a $315,000 Clinical Trial Planning Grant from the NIH’s National Center for Advancing Translational Sciences to finalize a Phase II trial of incyclinide. The drug is its candidate for treatment of hospitalized COVID-19 patients. The drug is a non-antimicrobial tetracycline formulation, which is the specialty of CMTx. “Incyclinide has already been shown to be highly effective in a number of animal models of acute respiratory distress syndrome across several species,” noted Lorne Golub, co-founder of CMTx and SUNY Distinguished Professor of Oral Biology and Pathology. Non-COVID-19-Related Merck presented new data from the Phase III CLEAR trial (KEYNOTE-581/Study 307) of its checkpoint inhibitor Keytruda (pembrolizumab) and Eisai’s tyrosine kinase inhibitor Lenvima (lenvatinib) in renal cell carcinoma. The combination of Keytruda and Lenvima was compared to Lenvima plus everolimus versus Pfizer’s Sutent (sunitinib) for first-line treatment of patients with advanced renal cell carcinoma (RCC). The combination of Keytruda and Lenvima demonstrated statistically significant and clinically meaningful improvements in progression-free survival (PFS), overall survival (OS) and objective response rate (ORR) compared to sunitinib. The Lenvima-everolimus combination also demonstrated statistically significant improvements in PFS and ORR compared to sunitinib. In exploratory analysis, the data for PFS and OS were consistent across prespecified Memorial Sloan Kettering Cancer Center (MSKCC) risk groups, in other words, favorable, intermediate, and poor. bluebird bio announced that it has placed its Phase I/II and Phase III trial of LentiGlobin gene therapy for sickle cell disease (SCD) on temporary suspension. The cause is a Suspected Unexpected Serious Adverse Reaction (SUSAR) of acute myeloid leukemia (AML). HGB-206 is the company’s ongoing Phase I/II trial of LentiGlobin for SCD. It includes three cohorts, A, B and C. In Group C, a refined manufacturing process designed to increase vector copy number was used. Group C also received LentiGlobin for SCD manufactured from hematopoietic (blood) stem cells (HSCs) collected from peripheral blood after mobilization with plerixafor, instead of by way of bone marrow harvest, which was the method used in Groups A and B. HGB-210 is their ongoing Phase III single-arm open-label trial. It is evaluating efficacy and safety of LentiGlobin for SCD in patients between two years and 50 years of age with sickle cell disease. Histogen announced week 26 results from its Phase Ib/IIa trial of HST-001 in male patients with androgenic alopecia—hair loss. At the timepoint, patients receiving the drug demonstrated statistically significant change from baseline in total hairs in the target area. HST-001, or Hair Stimulating Complex (HSC), is designed to be a physician-administered treatment for hair loss. Recce Pharmaceuticals formalized a deal with Fiona Stanley Hospital in Australia for a Phase I/II trial of RECCE 327, its new spray-on, broad-spectrum antibiotic for topical burn wound infections. It will enroll up to 30 patients. Eli Lilly announced results from its SURPASS-3 and SURPASS-5 Phase III trials after 52 weeks and 40 weeks, respectively. SURPASS-3 compared tirzepatide to titrated insulin degludec and SURPASS-5 compared tirzepatide to placebo, both as an add-on to titrated insulin glargine. All primary and all key secondary endpoints were met. Tirzepatide is a once-weekly dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist being evaluated for type 2 diabetes. The drug significantly reduced A1C and body weight in type 2 diabetes. Selecta Biosciences and AskBio initiated first-in-human dose escalation Phase I trial of SEL-399. SEL-399 is an AAV serotype 8 empty vector capsid containing no DNA combined with ImmTOR. The trial is to determine the optimal dose of ImmTOR to mitigate the formation of antibodies to AAV8 capsids used in gene therapies. Salarius Pharmaceuticals completed the dose-escalation stage and established the recommended Phase II dose for its ongoing Phase I/II trial for seclidemstat in r/r Ewing sarcoma. Seclidemstat is a novel, oral reversible inhibitor of the lysine-specific histone demethylase 1 enzyme (LSD1), which plays a key role in the development and progression of certain cancers. AstraZeneca and Merck announced the OlympiA Phase III trial for Lynparza (Olaparib) will move to early primary analysis and reporting after a recommendation from the Independent Data Monitoring Committee (IDMC). The IDMC decided the trial crossed the superiority boundary for its primary endpoint of invasive disease-free survival (iDFS) and demonstrated a sustainable, clinically relevant treatment effect for Lynparza compared to placebo for patients with germline BRCA-mutated high-risk HER2-negative early breast cancer. Ocuphire Pharma initiated enrollment in its Phase II VEGA-1 trial of a combination kit of Nyxol and low-dose pilocarpine in presbyopia. Nyxol is believed to improve near vision based on its ability to reduce pupil diameter, which results in increased depth of field. Dermavant Sciences announced positive safety and efficacy data from a planned interim analysis of PSOARING 3 of tapinarof in adults with plaque psoriasis. Tapinarof is a novel, once-daily aryl hydrocarbon receptor modulating agent (TAMA). Flexion Therapeutics announced plans to advance FX201 into the high dose cohort of the Phase I trial. FX201 is an intra-articular, IL-1Ra gene therapy product for osteoarthritis. ChemoCentryx published data from its Phase III ADVOCATE trial of avacopan in patients with anti-neutrophil cytoplasmic autoantibody-associated vasculitis (ANCA-associated vasculitis or ANCA vasculitis). Avacopan is an oral selective complement 51 receptor inhibitor. Treatment with avacopan in the absence of daily oral prednisone led to remission at week 26 and superiority in sustaining remission at 52 weeks compared to the prednisone group. vTv Therapeutics initiated its Phase I trial of orally administered phosphodiesterase type 4 inhibitor, HPP737 in healthy adults. The drug is being developed for the treatment of psoriasis. Most Read Today

VaccineGene TherapyAntibodySmall molecular drug

19 Feb 2021

·www.biospace.com

COVID-19 Update: Novavax, Bill Gates, J&J and More

There’s plenty of COVID-19-related news today. Here’s a look. Novavax Inks MoU with Gavi for 1.1 Billion Doses of COVID-19 Vaccine Novavax announced a Memorandum of Understanding (MOU) with Gavi, the Vaccine Alliance, to provide 1.1 billion doses of NVX-CoV2373, its COVID-19 vaccine candidate, for the COVAX Facility. The vaccine will be manufactured and distributed around the world by Novavax and Serum Institute of India (SII). SII has an existing deal with Gavi. Currently, the vaccine is being evaluated in two ongoing pivotal Phase III trials in the U.S. and Mexico, as well as the UK. On January 28, the company reported positive interim data from the UK trial. The vaccine demonstrated efficacy of 95.6% against the original Wuhan wildtype strain and 85.6% against the U.K. variant. Novavax also reported progress from its ongoing Phase IIb trial in South Africa, demonstrating a 60% efficacy. That study included HIV-positive patients, who had a 49% efficacy against the South African variant. Biden Administration Pledging $4 Billion to Global Vaccination Effort The Biden Administration has agreed to make good on last year’s pledge to donate $4 billion to a global program to distribute COVID-19 vaccines around the world. The deal was approved last year by the Democratic-led House and Republican led-Senate during President Donald Trump’s tenure. The international effort is COVAX, and as noted above, is being helped along by a deal with Novavax. Bill Gates Praises J&J and Novavax Vaccines for Capability Against Variants Bill Gates told CNBC that Johnson & Johnson and Novavax’s COVID-19 vaccines are showing a lot of promise against the emerging variants, such as those first appearing in the U.K., South Africa and Brazil. The Novavax vaccine demonstrated about a 90% efficacy in the U.K., but a 49% efficacy in South Africa, although a big part of that group was HIV-positive immunocompromised patients. The J&J vaccine was 66% effective overall, but about 57% effective in South Africa. J&J Submitted to WHO for Emergency Use Listing Johnson & Johnson Family of Companies submitted for Emergency Use Listing (EUL) to the WHO for its one-shot COVID-19 vaccine. The submission included interim efficacy and safety data from the Phase III ENSEMBLE trial. This completes its rolling submission to WHO. In December 2020, J&J signed an agreement in principle with Gavi to provide up to 500 million doses of the vaccine through 2022. The vaccine has also been submitted to the FDA for an EUA, with an advisory committee meeting scheduled for February 26, and also submitted for Conditional Marketing Authorization in Europe. Vaccine Hoarding and Shipping Problems Problems finding and scheduling the second shots of the Pfizer-BioNTech and Moderna vaccines in the U.S. are creating frustration and worry. Some regions have held doses in reserve to ensure the second dose, which overall slowed the pace of the initial vaccinations. There have also been some issues with shipping. For example, in Anne Arundel County, in the Washington DC region, a data error disrupted shipments for a time, forcing public health authorities to cancel two second-dose clinics. A similar situation occurred in Harford County, when hundreds of people trying to get their first shot disrupted a second-shot clinic. “The system has been so disordered and chaotic that it’s led to panic,” stated Maryland state Sen. James C. Rosapepe (D-Prince George’s). On the other hand, public health officials in Montgomery County said they avoided cancellations by not scheduling second-dose appointments at the time of the first shots. Instead, they email residents four to seven days prior to the second dose, telling them to visit a website where they can make their appointment. Fauci: Vaccine for Variants Could Take Months Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID), suggested that a vaccine for variant strains, such as the South African mutation, will likely take “several months.” He added, “We’re already, for example, working with the Moderna company. Pfizer’s doing it on their own, I’m sure. It’s a good company, a big company. But what we’re doing is, we’re working with them to get a sample of the vaccine that you can actually have it code for the protein that’s the appropriate protein for the South African isolate.” At this time, it’s not clear if they will be needed. The primary factor will be if people completely vaccinated with the Pfizer-BioNTech or Moderna vaccines begin showing up with severe COVID-19 in the hospital or dying from it. Currently, most tests and trials are suggesting the existing vaccines are effective against the variants, although not as effective as they are against the wildtype Wuhan strain. Pfizer and BioNTech Initiated Vaccine Trial in Pregnant Women Pfizer and BioNTech dosed the first patients in a clinical trial of 4,000 women in the late stages of pregnancy yesterday. The two companies will run the Phase II trial for 350 volunteers between 27 and 34 weeks’ gestation to confirm safety before moving into the Phase III portion for women between 24 and 34 weeks of pregnancy. AstraZeneca and Johnson & Johnson also plan to run trials in the coming months on pregnant women. “While it’s good news that vaccine trials in pregnant women are finally beginning, the results from these trials are unlikely to be available before the autumn,” said Marian Knight, professor of maternal and child population health at the University of Oxford. Israel Study Shows Pfizer-VioNTech Vaccine has 85% Efficacy After 1st Shot A study out of Israel demonstrated that a single dose of the Pfizer-BioNTech has 85% efficacy in preventing symptomatic disease 15 to 28 days after being dosed. In addition, there was a 75% decrease in all COVID-19 infections, symptomatic or asymptomatic. They do not know how long the single dose protection would last. A two-dose regimen has an efficacy of 95% a week after the second shot. An earlier trial by Pfizer and BioNTech demonstrated an efficacy of 52.4% after a single shot, but that study didn’t differentiate between before and after two weeks. Problems Finding Vaccine Ingredients From a historical perspective, the development and scale-up of the COVID-19 vaccines has been nothing short of amazing, there are naturally some unexpected problems. One of them is difficulties in finding some of the basic ingredients needed. For example, Acuitas Therapeutics, a biotechnology company in Vancouver, BC (Canada), has only 30 staffers and leases its facilities from the University of British Columbia. Acuitas’ proprietary molecule, an ionizable cationic lipid, is a required piece of the mRNA vaccine by Pfizer-BioNTech, and the demand is enormous. The company previously outsourced production of only small volumes of the lipid nanoparticles. “It’s on a scale that hasn’t been done before,” said Pieter Cullis, chairman of Acuitis, who is also one of the early developers of lipid nanoparticle technology. CMTx Biotech Received $315,000 Grant from the NIH for Phase II Trial of Incyclinide CMTx Biotech received a $315,000 Clinical Trial Planning Grant from the NIH’s National Center for Advancing Translational Sciences to finalize a Phase II trial of incyclinide. The drug is its candidate for treatment of hospitalized COVID-19 patients. The drug is a non-antimicrobial tetracycline formulation, which is the specialty of CMTx. “Incyclinide has already been shown to be highly effective in a number of animal models of acute respiratory distress syndrome across several species,” noted Lorne Golub, co-founder of CMTx and SUNY Distinguished Professor of Oral Biology and Pathology. Most Read Today

VaccinemRNA

100 Deals associated with Incyclinide

External Link

KEGG	Wiki	ATC	Drug Bank
D04519	Incyclinide	-	DB11647

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acne Vulgaris	Phase 2	US	CollaGenex Pharmaceuticals, Inc.	-
Acne Vulgaris	Phase 2	-	Galderma International SAS	-
Acute Lung Injury	Phase 2	US	CollaGenex Pharmaceuticals, Inc.	-
Cardiovascular Diseases	Phase 2	US	CollaGenex Pharmaceuticals, Inc.	-
Inflammation	Phase 2	US	CollaGenex Pharmaceuticals, Inc.	-
Mycoses	Phase 2	US	CollaGenex Pharmaceuticals, Inc.	-
Periodontal Diseases	Phase 2	US	CollaGenex Pharmaceuticals, Inc.	-
Rosacea	Phase 2	-	Galderma International SAS	-
Rosacea	Phase 2	US	CollaGenex Pharmaceuticals, Inc.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00004147 (Pubmed \| J Neurooncol)	Phase 1	Recurrent Malignant Glioma	-	COL-3	(ukevxitmlj) = epczgpwfmq ukpvltkcff (lvresycbge )	-	01 Nov 2011

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis